Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 8
2012 9
2013 5
2014 9
2015 13
2016 17
2017 20
2018 10
2019 19
2020 17
2021 22
2022 22
2023 15
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Results by year

Filters applied: . Clear all
Page 1
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM, McConkey DJ, McGuire BM, Bivalacqua TJ, Kates M, Matoso A. Hoffman-Censits JH, et al. Among authors: kates m. Appl Immunohistochem Mol Morphol. 2021 Sep 1;29(8):619-625. doi: 10.1097/PAI.0000000000000938. Appl Immunohistochem Mol Morphol. 2021. PMID: 33901032 Free PMC article.
Reply by Authors.
Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ. Chappidi MR, et al. Among authors: kates m. J Urol. 2020 Mar;203(3):552-553. doi: 10.1097/JU.0000000000000522.03. Epub 2019 Nov 26. J Urol. 2020. PMID: 31769720 No abstract available.
Reply by Authors.
Patel SH, Gabrielson AT, Chan S, Schwartz D, Collins C, Singla N, Trock B, Bivalacqua TJ, Hahn N, Kates MR. Patel SH, et al. Among authors: kates mr. J Urol. 2024 May 7:101097JU0000000000004017. doi: 10.1097/JU.0000000000004017. Online ahead of print. J Urol. 2024. PMID: 38713596 No abstract available.
Editorial Comment.
Kates M. Kates M. J Urol. 2019 Oct;202(4):769. doi: 10.1097/01.JU.0000576700.56544.da. Epub 2019 Sep 6. J Urol. 2019. PMID: 31287762 No abstract available.
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: kates m. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821066
Tissue-engineered urinary conduits.
Kates M, Singh A, Matsui H, Steinberg GD, Smith ND, Schoenberg MP, Bivalacqua TJ. Kates M, et al. Curr Urol Rep. 2015 Mar;16(3):8. doi: 10.1007/s11934-015-0480-3. Curr Urol Rep. 2015. PMID: 25677229 Review.
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer.
Singh AK, Praharaj M, Lombardo KA, Yoshida T, Matoso A, Baras AS, Zhao L, Srikrishna G, Huang J, Prasad P, Powell JD, Kates M, McConkey D, Pardoll DM, Bishai WR, Bivalacqua TJ. Singh AK, et al. Among authors: kates m. Nat Commun. 2022 Feb 15;13(1):878. doi: 10.1038/s41467-022-28509-z. Nat Commun. 2022. PMID: 35169141 Free PMC article.
142 results